Breast Cancer Treatment Strategies: AI ± CDK4/6 Inhibitors, Biomarkers, and ESR1 Mutations
By
Manali Bhave, MD, Nadia Harbeck, MD, PhD
Summary
This article appears to be a medical education piece focused on breast cancer treatment strategies, specifically discussing patients progressing on AI (aromatase inhibitors) with or without CDK4/6 inhibitors. It covers biomarkers and treatment strategies, featuring faculty from Emory University and LMU University Hospital. The content is likely an accredited continuing medical education (CME) activity from Medscape, targeting healthcare professionals. It mentions acquired ESR1 mutations increasing after endocrine therapy exposure.
Source
Twitter / XBreast Cancer Treatment Strategies: AI ± CDK4/6 Inhibitors, Biomarkers, and ESR1 Mutationsmdsc.peKey quotes
· 2 pulledDid you know that the prevalence of acquired ESR1 mutations increases after exposure to endocrine therapy?
In support of improving patient care, Medscape, LLC is jointly accredited with c
You might also wanna read
Targeting genomic instability: From chemotherapy to precision medicine in cancer treatment
This article examines genomic instability as a hallmark of cancer, explaining how it drives malignant transformation through accumulated gen
UC San Diego AI Model Predicts Cancer Treatment Response from Tumor Genetics
UC San Diego researchers have developed an AI tool called iAtlas that can predict how a tumor will respond to treatment based solely on its
Ask HN: What is the latest on treatment of Metastatic Breast Cancer?
Compound UNI418 disrupts cancer DNA repair to overcome drug resistance
Researchers have discovered that cancer cells survive DNA-damaging treatments by using sophisticated repair systems like homologous recombin
AI Advances in Drug Discovery: From Data Integration to Dual-Action Cancer Drug Design
The article discusses recent advancements in AI-driven drug discovery, highlighting two key developments: 1) Analytica 2026, an event focuse
drugtargetreview.com·4mo ago
Genomic test trial suggests hormone therapy alone may be sufficient for low-risk breast cancer patients
A groundbreaking genomic test trial suggests that breast cancer patients with low test scores could be treated with hormone therapy alone, a
apple.news·22d agoComments
Sign in to join the conversation.
No comments yet. Be the first.